



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/700,548	11/05/2003	Laurence Gerald Hughes	Q78134	6075
23373	7590	08/17/2007	EXAMINER	
SUGHRUE MION, PLLC			AZPURU, CARLOS A	
2100 PENNSYLVANIA AVENUE, N.W.				
SUITE 800			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20037			1615	
			MAIL DATE	DELIVERY MODE
			08/17/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/700,548	HUGHES ET AL.
	<b>Examiner</b> Carlos A. Azpuru	<b>Art Unit</b> 1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 06 August 2007.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 60-69, 73-83 and 85-90 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 60-69, 73-83, 85-90 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

**DETAILED ACTION**

Receipt is acknowledged of the amendment filed 08/06/2006.

The rejection under 35 USC 102(e) is hereby withdrawn.

Applicant's remarks have been noted. Further, as agreed in the telephonic interview of August 1, 2007, while the rejection under 35 USC 103(a) will be maintained, because all the claims were not included in the final rejection applicant will be given a chance to respond by making this action non-final.

The following rejections are maintained in this action:

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 60-69, 73-83, 85-90 are rejected under 35 US 103(a) as being unpatentable over Porssa et al further in view of both WO-A-98/15575 (WO'575) and US Pat No. 5,674,192 (US'192).

Porssa et al disclose a polymer formed from the combination of a zwitterionic monomer, a cationic monomer, and a hydrophobic termonomer (see Abstract), a coated stent thereof, and a method of coating the stent with said polymer. The new terpolymer has formulae disclosed at col. 2, lines 21-67 and include YBX, Y B Q, and Y B Q. Substituents are defined just as they in the instant claims (see cols. 4-7 for the definitions of each). A coating process is set out in claims 17-25, while the polymer coating is set out in claims 1-16. While the disclosure of Porssa et al is silent as to the thickness of the coating once dry, the identical polymer is used to coat a stent in the same process steps. Porssa et al further disclose drug delivery at col. 6, line 63. Specific delivery of proteins and nucleic acids is not set out.

However, delivery of sense and antisense DNA from stents is set out in WO'5575. US '192 not only discloses delivery of nucleic acids, but monoclonal antibodies (proteins) from a hydrogel coating of a stent. As such, the ordinary practitioner would have found it well within his or her skill to use the disclosed coating of Porssa et al for drug delivery as suggested therein, and further, to specifically delivery both nucleic acids and proteins as suggested by WO'575 and US'192. These ordinary practitioners would have further expected similar therapeutic benefits from the delivery of such agents given the teachings of Porssa et al in view of both WO'575 and US'192. As such, the instantly claimed delivery of either nucleic acids or proteins would have

obvious at the time of invention given the disclosures of Porssa et al in view of both WO'575 and US'192.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 60-69, 73-83, 85-90 are provisionally rejected on the ground of nonstatutory

obviousness-type double patenting as being unpatentable over claims 1-84 of copending Application No. 10,842,416 (US'416) in view of WO'575 and US'192.

US'416 disclose a method of coating an implant such as a stent using the instantly claimed polymers, addition steps, evaporation, and coating thickness. US'416 is silent as to the specific drugs which may be delivered using this coating.

However, delivery of sense and antisense DNA from stents is set out in WO'5575. US '192 not only discloses delivery of nucleic acids, but monoclonal antibodies (proteins) from a hydrogel coating of a stent. As such, the ordinary practitioner would have found it well within his or her skill to use the claimed coating of US'416 for drug delivery as suggested therein, and further, to specifically delivery both nucleic acids and proteins as suggested by WO'575 and US'192. These ordinary practitioners would have further expected similar therapeutic benefits from the delivery of such agents given the claimed coating US'416 in view of both WO'575 and US'192. As such, the instantly claimed delivery of either nucleic acids or proteins would have obvious at the time of invention given the claims of US'416 in view of both WO'575 and US'192.

This is a provisional obviousness-type double patenting rejection.

***Response to Arguments***

Applicant's arguments filed 08/06/2007 have been fully considered but they are not persuasive.


Applicant correctly points to the lack of incorporation of limitations from claim 39 into claims 77 and 89. However, as stated during the interview of 08/01/2007, these claims were not included in the final rejection through an oversight. However, as stated in the final rejection the incorporation of either proteins or nucleic acids into a stent hydrogel coating is well known in the art as shown by Porssa et al in view of WO'575 and US'192. As such, the rejection under 35 USC 103(a) is hereby maintained.

With regard to the rejection under the judicially created doctrine of obviousness-type double patenting, applicant states that copending US'416 is silent as to the pendant zwiterionic and cationic groups. However, the same polymer subunits are defined by the claims of US'416. Those of ordinary skill would expect the same pendant groups to be present in the instant claims given that the claims of US'416 define the same polymer. Further, those of ordinary skill would have a reasonable expectation of similar therapeutic results from the use of the instant polymer as a stent coating and drug delivery system given the claims of Us'416. As such, the obviousness-type double patenting rejection is hereby maintained in this action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlos A. Azpuru whose telephone number is (571) 272-0588. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

  
Carlos A. Azpuru  
Primary Examiner  
Art Unit 1615

ca